Comparative safety and effectiveness of standard doses of apixaban versus dabigatran, rivaroxaban, and VKAs in non-valvular atrial fibrillation patients in France: the NAXOS study

被引：0
|
作者：
Danchin, N. [1 ]
Steg, P. G. [2 ]
Hanon, O. [3 ]
Mahe, I. [4 ]
Belhassen, M. [5 ]
Jacoud, F. [5 ]
Nolin, M. [5 ]
Ginoux, M. [5 ]
Dalon, F. [5 ]
Lefevre, C. [6 ]
Cotte, F. E. [6 ]
Gollety, S. [6 ]
Falissard, B. [7 ]
Van Ganse, E. [5 ]
机构：
[1] Hop Europeen Georges Pompidou, Cardiol, Paris, France
[2] Univ Paris Diderot, Bichat Hosp, FACT, INSERM,UMR1148, Paris, France
[3] Hosp Broca Paris, Geriatr Med, Paris, France
[4] Paris Diderot Univ, Hosp Louis Mourier, AP HP, Internal Med,INSERM,UMR 1140, Colombes, France
[5] Pharmacoepidemiol Lyon PELyon, Lyon, France
[6] Bristol Myers Squibb, Rueil Malmaison, France
[7] Ctr Res Epidemiol & Populat Hlth, INSERM, U1018, CESP, Paris, France
来源：
EUROPEAN HEART JOURNAL | 2019年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1255
引用
收藏
页码：711 / 711
页数：1
相关论文
共 50 条
  • [31] Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation
    不详
    [J]. ANNALS OF INTERNAL MEDICINE, 2020, 172 (07) : 463 - 473
  • [32] COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN SPAIN
    Canal Fontcuberta, G.
    Escolar Albaladejo, G.
    Betegon Nicolas, L.
    de Salas-Cansado, M.
    Rubio-Rodriguez, D.
    Rubio-Terres, G.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
  • [33] Comparative Safety and Efficacy of Rivaroxaban, Dabigatran and Apixaban in Obese and Morbidly Obese Patients With Heart Failure and Non-Valvular Atrial Fibrillation: A Real World Analysis
    Chugh, Yashasvi
    Krishna, Hanumanthu B.
    Ayala, Renato Q.
    Zepeda, Ignacio
    Li Dan
    Gonzalez, Carola A.
    Patel, Kavisha
    Gongora, Carlos
    Kallur, Ramya
    Rastogi, Ujjwal
    Piplani, Shobhit
    Chugh, Sanjay K.
    Grushko, Michael
    Faillace, Robert T.
    [J]. CIRCULATION, 2018, 138
  • [34] COST - EFFECTIVENESS OF APIXABAN WITH OTHER NOACS (DABIGATRAN AND RIVAROXABAN) IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION (FANV) IN PATIENTS OF SOCIAL SECURITY OF PERU
    Sanabria, C.
    Cabrejos, J.
    Olortegui, A.
    Guevara, C.
    Garrido Lecca, S.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A829 - A829
  • [35] Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
    Lai, Chao-Lun
    Chen, Ho-Min
    Liao, Min-Tsun
    Lin, Ting-Tse
    Chan, K. Arnold
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (04):
  • [36] Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
    Li, Wei-Jia
    Archontakis-Barakakis, Paraschos
    Palaiodimos, Leonidas
    Kalaitzoglou, Dimitrios
    Tzelves, Lazaros
    Manolopoulos, Apostolos
    Wang, Yu-Chiang
    Giannopoulos, Stefanos
    Faillace, Robert
    Kokkinidis, Damianos G.
    [J]. WORLD JOURNAL OF CARDIOLOGY, 2021, 13 (04): : 82 - 94
  • [37] Characteristics and Clinical Outcomes of Patients Using Rivaroxaban Versus Dabigatran for Non-Valvular Atrial Fibrillation.
    Mahfouz, Ahmed
    Abu Yousef, Safae
    Hamou, Fatima
    Aljundi, Amer
    AlYafei, Sumaya
    Singh, Rajvir
    [J]. PHARMACOTHERAPY, 2018, 38 (04): : E31 - E31
  • [38] Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis
    Koretsune, Yukihiro
    Yamashita, Takeshi
    Yasaka, Masahiro
    Ono, Yasuhisa
    Hirakawa, Takeshi
    Ishida, Kosuke
    Kuroki, Daisuke
    Sumida, Toshiyuki
    Urushihara, Hisashi
    [J]. JOURNAL OF CARDIOLOGY, 2019, 73 (3-4) : 204 - 209
  • [39] Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Among Morbidly Obese Patients With Non-Valvular Atrial Fibrillation
    Peterson, Eric D.
    Ashton, Veronica
    Chen, Yen-Wen
    Wu, Bingcao
    Mangla, Kamal Kant
    Spyropoulos, Alex C.
    [J]. CIRCULATION, 2018, 138
  • [40] 2 Point Plasma Dabigatran, Rivaroxaban and Apixaban Levels in Patientswith Non-Valvular Atrial Fibrillation: A Single Centre Study
    Lim, M. S. H.
    Tiong, L. L.
    Tan, S. S. N.
    Ku, M. Y.
    Charles, S.
    Ong, T. K.
    Fong, A. Y. Y.
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 249 : S26 - S27
12345